These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 21357511)
1. Rapamycin inhibits hydrogen peroxide-induced loss of vascular contractility. Gao G; Li JJ; Li Y; Li D; Wang Y; Wang L; Tang XD; Walsh MP; Gui Y; Zheng XL Am J Physiol Heart Circ Physiol; 2011 May; 300(5):H1583-94. PubMed ID: 21357511 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function. Li SY; Fang CX; Aberle NS; Ren BH; Ceylan-Isik AF; Ren J J Endocrinol; 2005 Sep; 186(3):491-503. PubMed ID: 16135669 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Yu JJ; Zhang Y; Wang Y; Wen ZY; Liu XH; Qin J; Yang JL Psychopharmacology (Berl); 2013 Jan; 225(2):361-72. PubMed ID: 22875481 [TBL] [Abstract][Full Text] [Related]
4. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. Hafizi S; Wang X; Chester AH; Yacoub MH; Proud CG Am J Physiol Heart Circ Physiol; 2004 Sep; 287(3):H1232-8. PubMed ID: 15317677 [TBL] [Abstract][Full Text] [Related]
5. The mTOR/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Boluyt MO; Li ZB; Loyd AM; Scalia AF; Cirrincione GM; Jackson RR Cardiovasc Drugs Ther; 2004 Jul; 18(4):257-67. PubMed ID: 15367823 [TBL] [Abstract][Full Text] [Related]
6. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559 [TBL] [Abstract][Full Text] [Related]
7. Effect of different immunosuppressive drugs on immune cells from young and old healthy persons. Welzl K; Kern G; Mayer G; Weinberger B; Säemann MD; Sturm G; Grubeck-Loebenstein B; Koppelstaetter C Gerontology; 2014; 60(3):229-38. PubMed ID: 24434865 [TBL] [Abstract][Full Text] [Related]
8. The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration. Albawardi A; Almarzooqi S; Saraswathiamma D; Abdul-Kader HM; Souid AK; Alfazari AS Int J Clin Exp Pathol; 2015; 8(3):2955-62. PubMed ID: 26045804 [TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193 [TBL] [Abstract][Full Text] [Related]
10. Strain-induced vascular endothelial cell proliferation requires PI3K-dependent mTOR-4E-BP1 signal pathway. Li W; Sumpio BE Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1591-7. PubMed ID: 15591103 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. El-Chaâr D; Gagnon A; Sorisky A Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836 [TBL] [Abstract][Full Text] [Related]
12. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
13. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells. Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512 [TBL] [Abstract][Full Text] [Related]
14. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Wang L; Wang X; Proud CG Am J Physiol Heart Circ Physiol; 2000 Apr; 278(4):H1056-68. PubMed ID: 10749698 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the mTOR pathway in abdominal aortic aneurysm: implications of smooth muscle cell contractile phenotype, inflammation, and aneurysm expansion. Li G; Qin L; Wang L; Li X; Caulk AW; Zhang J; Chen PY; Xin S Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1110-H1119. PubMed ID: 28213405 [TBL] [Abstract][Full Text] [Related]
16. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Martin KA; Rzucidlo EM; Merenick BL; Fingar DC; Brown DJ; Wagner RJ; Powell RJ Am J Physiol Cell Physiol; 2004 Mar; 286(3):C507-17. PubMed ID: 14592809 [TBL] [Abstract][Full Text] [Related]
17. The immunosuppressant tributyltin oxide blocks the mTOR pathway, like rapamycin, albeit by a different mechanism. Osman AM; van Loveren H J Appl Toxicol; 2014 Dec; 34(12):1361-7. PubMed ID: 24375594 [TBL] [Abstract][Full Text] [Related]
18. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909 [TBL] [Abstract][Full Text] [Related]